Pfizer and BioNTech Vaccine Can Be Used In Europe Before The Year Ends

Pfizer and BioNTech Vaccine Can Be Used In Europe Before The Year Ends Pfizer and BioNTech vaccine can be used in Europe before the year ends. Companies applied to the relevant institution. Pfizer and its partner BioNTech applied to the regulatory organizations in Europe for permission for the vaccine they developed. Following the official application made on Monday, the vaccine audit in Europe, which started on October 6, is expected to accelerate the approval process and the vaccine to be approved before the end of the year. The vaccine developed by Pfizer and BioNTech was tested on 44 thousand people in November; While preventing 95 percent of symptomatic cases, it did not cause any serious adverse effects.   Companies Compete with Each Other As companies compete to find and administer the vaccine, regulators around the world are competing with each other to review vaccination data and end the epidemic by administering the vaccine to their populations. Moderna also submitted applications to the necessary organizations in the US and Europe on Monday. If the European Medicines Agency considers that the benefits of Pfizer and BioNtech's vaccines outweigh the risks, it may make a recommendation on granting a conditional authorization. In this case, the vaccine can be administered in Europe before the year ends.